Aimei Health Tech Confirms Nasdaq Listing for Shares, Rights, Units

TL;DR

**AFJK confirms Nasdaq listing for all securities, business as usual.**

AI Summary

Aimei Health Technology Co., Ltd. (AFJK) filed an 8-K on January 18, 2024, confirming its various securities, including Ordinary Shares (AFJK), Rights (AFJKR), and Units (AFJKU), are registered on The Nasdaq Stock Market LLC. This filing is a routine update, indicating the company is maintaining its listing compliance. For investors, this means AFJK continues to meet the requirements to trade on a major exchange, providing liquidity and transparency for its stock.

Why It Matters

This filing confirms Aimei Health Technology Co., Ltd.'s continued compliance with Nasdaq listing requirements, which is crucial for maintaining investor confidence and market access.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing confirming existing listing status, posing minimal risk to investors.

Analyst Insight

A smart investor would view this as a routine compliance filing, indicating no immediate change in the company's operational or financial status. It reinforces the company's continued presence on a major exchange, which is a positive for liquidity and transparency, but doesn't warrant any specific trading action based solely on this information.

Key Players & Entities

• Aimei Health Technology Co., Ltd. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where AFJK's securities are registered
• AFJK (company) — trading symbol for Ordinary Shares
• AFJKR (company) — trading symbol for Rights
• AFJKU (company) — trading symbol for Units
• January 18, 2024 (date) — date of earliest event reported and filing date

FAQ

Filing Documents

• form8-k.htm (8-K) — 42KB
• ex99-1.htm (EX-99.1) — 10KB
• 0001493152-24-002911.txt ( ) — 269KB
• afjk-20240118.xsd (EX-101.SCH) — 4KB
• afjk-20240118_def.xml (EX-101.DEF) — 26KB
• afjk-20240118_lab.xml (EX-101.LAB) — 36KB
• afjk-20240118_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 6KB

From the Filing

U nited SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 18, 2024 Date of Report (Date of earliest event reported) AIMEI HEALTH TECHNOLOGY CO., LTD (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-41880 N/A (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 10 East 53rd Street , Suite 3001 New York , NY 10022 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: +34 678 035200 N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act Soliciting material pursuant to Rule 14a-12 under the Exchange Act Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares AFJK The Nasdaq Stock Market LLC Rights AFJKR The Nasdaq Stock Market LLC Units AFJKU The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events On January 18, 2024, Aimei Health Technology Co., LTD. (the " Company ") issued a press release, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K, announcing that the holders of the Company's units (the " Units ") may elect to separately trade the ordinary shares and rights included in the Units commencing on January 22, 2024. Each unit consists of one ordinary share and one right. Each right entitles the holder thereof to receive one-fifth (1/5) of one ordinary share upon the consummation of an initial business combination. Any Unit not separated will continue to trade on the Nasdaq Global Market (" Nasdaq ") under the symbol "AFJKU," and the ordinary shares and rights will separately trade on Nasdaq under the symbols "AFJK" and "AFJKR," respectively. Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the Units into ordinary shares and rights. Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated January 18, 2024 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIMEI HEALTH TECHNOLOGY CO., LTD By: /s/ Juan Fernandez Pascual Name: Juan Fernandez Pascual Title: Chief Executive Officer Dated: January 18, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR